Topic: point-of-care diagnostics
Mammoth Biosciences is harnessing CRISPR to create diagnostic tools that can detect any biomarker containing DNA or RNA. It just added Cas14 to its arsenal.
Danaher’s point-of-care focused HemoCue subsidiary has launched its newest hemoglobin test in the U.S. following a recent 510(k) clearance.
Sight Diagnostics, maker of point-of-care blood diagnostic hardware, raised $27.8 million to continue its expansion and fund U.S. regulatory efforts.
Ceribell raised $35 million for its rapid-response EEG headband that quickly diagnoses patients suspected of having seizures with no visual symptoms.
MeMed raised $70 million for its immune system diagnostic for distinguishing between bacterial and viral infections, to reduce antibiotic misuse.
Diagnostic maker Echosens is teaming up with a consortium of health systems to develop a real-world evidence model to help standardize care for NASH.
Diassess was awarded a federal contract worth up to $21.9 million to develop an at-home flu diagnostic test.
Sight Diagnostics received a CE mark for its point-of-care blood diagnostic that uses AI to optically read samples and provide complete blood counts.
Biodesix acquired Integrated Diagnostics and its XL2 lung cancer blood test, which aims to help screen patients that can avoid nodule biopsies.
The $4.4 million award sets Talis up to work on a molecular diagnostic capable of detecting the bacteria in patient samples within 20 minutes.